Five-year data from the Phase 2 GALAXI 1 trial show that Tremfya delivered durable clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease, providing the longest follow-up reported to date for an IL-23 inhibitor in the condition.
Among patients who remained on treatment, 97.7% achieved clinical remission, all were corticosteroid-free, 71% achieved endoscopic response, and 51% achieved endoscopic remission after five years. The findings strengthen the case for IL-23-targeted therapies as a long-term treatment strategy for Crohn’s disease, particularly in patients who have previously failed other biologic therapies.